Systems for in vivo site-directed mutagenesis using oligonucleotides

Details for Australian Patent Application No. 2002319696 (hide)

Owner The Government of the United States of America as represented by the Secretary of Health and Human Services

Inventors Resnick, Michael A.; Storici, Francesca; Lewis, Lysle Kevin

Agent Griffith Hack

Pub. Number AU-B-2002319696

PCT Number PCT/US02/23634

PCT Pub. Number WO2003/012036

Priority 60/308,426 27.07.01 US

Filing date 26 July 2002

Wipo publication date 17 February 2003

Acceptance publication date 1 November 2007

International Classifications

C12N 15/09 (2006.01) Mutation or genetic engineering - Recombinant DNA-technology

C12N 15/10 (2006.01) Mutation or genetic engineering - Processes for the isolation, preparation or purification of DNA or RNA

C12N 15/65 (2006.01) Mutation or genetic engineering - using markers

C12N 15/90 (2006.01) Mutation or genetic engineering

Event Publications

16 January 2003 Complete Application Filed

  Priority application(s): 60/308,426 27.07.01 US

29 May 2003 Application Open to Public Inspection

  Published as AU-B-2002319696

1 November 2007 Application Accepted

  Published as AU-B-2002319696

28 February 2008 Standard Patent Sealed

24 February 2011 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2002319697-TANTALUM AND NIOBIUM BILLETS AND METHODS OF PRODUCING THE SAME

2002319695-Substituted piperidines as modulators of the melanocortin receptor